Exenatide: A New Promising Antidiabetic Agent |
| |
Authors: | C K Chakraborti |
| |
Institution: | Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela-769 015, India |
| |
Abstract: | Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin. |
| |
Keywords: | Exenatide exendin-4 glucagon-like peptide-1 glycosylated hemoglobin type 2 diabetes mellitus |
|
|